Yayın: Pharmacokinetics of cefquinome after single and repeated subcutaneous administrations in sheep
| dc.contributor.author | Corum, Orhan | |
| dc.contributor.author | Corum, Duygu Durna | |
| dc.contributor.author | Er, Ayse | |
| dc.contributor.author | Uney, Kamil | |
| dc.date.accessioned | 2026-01-04T12:42:05Z | |
| dc.date.issued | 2019-02-04 | |
| dc.description.abstract | AbstractThe purpose of this study was to determine the pharmacokinetics of cefquinome (CFQ) following single and repeated subcutaneous (SC) administrations in sheep. Six clinically healthy, 1.5 ± 0.2 years sheep were used for the study. In pharmacokinetic study, the crossover design in three periods was performed. The withdrawal interval between the study periods was 15 days. In first period, CFQ (Cobactan, 2.5%) was administered by an intravenous (IV) bolus (3 sheep) and SC (3 sheep) injections at 2.5 mg/kg dose. In second period, the treatment administration was repeated via the opposite administration route. In third period, CFQ was administrated subcutaneously to each sheep (n = 6) at a dose of 2.5 mg/kg q. 24 hr for 5 days. Plasma concentrations of CFQ were measured using the HPLC‐UV method. Pharmacokinetic parameters were calculated using non‐compartmental methods. The elimination half‐life and mean residence time of CFQ after the single SC administration were longer than IV administration (p < 0.05). Bioavailability (F%) of CFQ following the single SC administration was 123.51 ± 11.54%. The area under the curve (AUC0‐∞) and peak concentration following repeated doses (last dose) were higher than those observed after the first dose (p < 0.05). CFQ accumulated after repeated SC doses. CFQ can be given via SC at a dose of 2.5 mg/kg every 24 hr for the treatment of infections caused by susceptible pathogens, which minimum inhibitory concentration is ≤1.0 μg/ml in sheep. | |
| dc.description.uri | https://doi.org/10.1111/jvp.12750 | |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/30719732 | |
| dc.description.uri | https://dx.doi.org/10.1111/jvp.12750 | |
| dc.description.uri | https://hdl.handle.net/20.500.12395/38081 | |
| dc.identifier.doi | 10.1111/jvp.12750 | |
| dc.identifier.eissn | 1365-2885 | |
| dc.identifier.endpage | 653 | |
| dc.identifier.issn | 0140-7783 | |
| dc.identifier.openaire | doi_dedup___::567fd7dc39f5908a5eb01c103dd85d45 | |
| dc.identifier.orcid | 0000-0003-3168-2510 | |
| dc.identifier.orcid | 0000-0003-1567-991x | |
| dc.identifier.orcid | 0000-0002-8674-4873 | |
| dc.identifier.pubmed | 30719732 | |
| dc.identifier.scopus | 2-s2.0-85061200433 | |
| dc.identifier.startpage | 647 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/37228 | |
| dc.identifier.volume | 42 | |
| dc.identifier.wos | 000501034000010 | |
| dc.language.iso | eng | |
| dc.publisher | Wiley | |
| dc.relation.ispartof | Journal of Veterinary Pharmacology and Therapeutics | |
| dc.rights | OPEN | |
| dc.subject | sheep | |
| dc.subject | Sheep | |
| dc.subject | Bacteria | |
| dc.subject | Injections, Subcutaneous | |
| dc.subject | Microbial Sensitivity Tests | |
| dc.subject | Drug Administration Schedule | |
| dc.subject | Anti-Bacterial Agents | |
| dc.subject | Cephalosporins | |
| dc.subject | Area Under Curve | |
| dc.subject | Animals | |
| dc.subject | subcutaneous | |
| dc.subject | bioavailability | |
| dc.subject | pharmacokinetics | |
| dc.subject | cefquinome | |
| dc.subject | Half-Life | |
| dc.subject.sdg | 2. Zero hunger | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Pharmacokinetics of cefquinome after single and repeated subcutaneous administrations in sheep | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.api.response | {"authors":[{"fullName":"Orhan Corum","name":"Orhan","surname":"Corum","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}},{"fullName":"Duygu Durna Corum","name":"Duygu Durna","surname":"Corum","rank":2,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0003-1567-991x"},"provenance":null}},{"fullName":"Ayse Er","name":"Ayse","surname":"Er","rank":3,"pid":null},{"fullName":"Kamil Uney","name":"Kamil","surname":"Uney","rank":4,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"SDG","value":"2. Zero hunger"},"provenance":null},{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"sheep"},"provenance":null},{"subject":{"scheme":"keyword","value":"Sheep"},"provenance":null},{"subject":{"scheme":"keyword","value":"Bacteria"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Subcutaneous"},"provenance":null},{"subject":{"scheme":"keyword","value":"Microbial Sensitivity Tests"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Drug Administration Schedule"},"provenance":null},{"subject":{"scheme":"keyword","value":"Anti-Bacterial Agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cephalosporins"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Area Under Curve"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"subcutaneous"},"provenance":null},{"subject":{"scheme":"keyword","value":"bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"cefquinome"},"provenance":null},{"subject":{"scheme":"keyword","value":"Half-Life"},"provenance":null}],"mainTitle":"Pharmacokinetics of cefquinome after single and repeated subcutaneous administrations in sheep","subTitle":null,"descriptions":["<jats:title>Abstract</jats:title><jats:p>The purpose of this study was to determine the pharmacokinetics of cefquinome (<jats:styled-content style=\"fixed-case\">CFQ</jats:styled-content>) following single and repeated subcutaneous (<jats:styled-content style=\"fixed-case\">SC</jats:styled-content>) administrations in sheep. Six clinically healthy, 1.5 ± 0.2 years sheep were used for the study. In pharmacokinetic study, the crossover design in three periods was performed. The withdrawal interval between the study periods was 15 days. In first period, <jats:styled-content style=\"fixed-case\">CFQ</jats:styled-content> (Cobactan, 2.5%) was administered by an intravenous (<jats:styled-content style=\"fixed-case\">IV</jats:styled-content>) bolus (3 sheep) and <jats:styled-content style=\"fixed-case\">SC</jats:styled-content> (3 sheep) injections at 2.5 mg/kg dose. In second period, the treatment administration was repeated via the opposite administration route. In third period, <jats:styled-content style=\"fixed-case\">CFQ</jats:styled-content> was administrated subcutaneously to each sheep (<jats:italic>n</jats:italic> = 6) at a dose of 2.5 mg/kg q. 24 hr for 5 days. Plasma concentrations of CFQ were measured using the <jats:styled-content style=\"fixed-case\">HPLC</jats:styled-content>‐<jats:styled-content style=\"fixed-case\">UV</jats:styled-content> method. Pharmacokinetic parameters were calculated using non‐compartmental methods. The elimination half‐life and mean residence time of <jats:styled-content style=\"fixed-case\">CFQ</jats:styled-content> after the single <jats:styled-content style=\"fixed-case\">SC</jats:styled-content> administration were longer than <jats:styled-content style=\"fixed-case\">IV</jats:styled-content> administration (<jats:italic>p </jats:italic>< 0.05). Bioavailability (<jats:italic>F</jats:italic>%) of <jats:styled-content style=\"fixed-case\">CFQ</jats:styled-content> following the single <jats:styled-content style=\"fixed-case\">SC</jats:styled-content> administration was 123.51 ± 11.54%. The area under the curve (<jats:styled-content style=\"fixed-case\">AUC</jats:styled-content><jats:sub>0‐∞</jats:sub>) and peak concentration following repeated doses (last dose) were higher than those observed after the first dose (<jats:italic>p </jats:italic>< 0.05). <jats:styled-content style=\"fixed-case\">CFQ</jats:styled-content> accumulated after repeated <jats:styled-content style=\"fixed-case\">SC</jats:styled-content> doses. <jats:styled-content style=\"fixed-case\">CFQ</jats:styled-content> can be given via <jats:styled-content style=\"fixed-case\">SC</jats:styled-content> at a dose of 2.5 mg/kg every 24 hr for the treatment of infections caused by susceptible pathogens, which minimum inhibitory concentration is ≤1.0 μg/ml in sheep.</jats:p>"],"publicationDate":"2019-02-04","publisher":"Wiley","embargoEndDate":null,"sources":["Crossref"],"formats":["application/pdf"],"contributors":["Selcuk University Institutional Repository"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Journal of Veterinary Pharmacology and Therapeutics","issnPrinted":"0140-7783","issnOnline":"1365-2885","issnLinking":null,"ep":"653","iss":null,"sp":"647","vol":"42","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::567fd7dc39f5908a5eb01c103dd85d45","originalIds":["10.1111/jvp.12750","50|doiboost____|567fd7dc39f5908a5eb01c103dd85d45","30719732","2911676059","50|od______4883::b4937f501c53b3b897316cf100c0ff1c","oai:acikerisim.selcuk.edu.tr:20.500.12395/38081"],"pids":[{"scheme":"doi","value":"10.1111/jvp.12750"},{"scheme":"pmid","value":"30719732"},{"scheme":"handle","value":"20.500.12395/38081"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":9,"influence":2.8428278e-9,"popularity":5.9841994e-9,"impulse":5,"citationClass":"C5","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1111/jvp.12750"}],"license":"Wiley Online Library User Agreement","type":"Article","urls":["https://doi.org/10.1111/jvp.12750"],"publicationDate":"2019-02-04","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"30719732"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12750"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/30719732"],"publicationDate":"2020-04-28","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"mag_id","value":"2911676059"},{"scheme":"doi","value":"10.1111/jvp.12750"}],"type":"Article","urls":["https://dx.doi.org/10.1111/jvp.12750"],"refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"20.500.12395/38081"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12750"}],"type":"Article","urls":["https://hdl.handle.net/20.500.12395/38081","https://doi.org/10.1111/jvp.12750"],"publicationDate":"2019-01-01","refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false} | |
| local.import.source | OpenAire | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus | |
| local.indexed.at | PubMed |
